HIV/HBV coinfection in children and antiviral therapy

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 3, 2013, Pages 251-263

  Healy, Sara A ^a,b,c   Gupta, Sonia ^d   Melvin, Ann J ^b,c  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

antiviral treatment; coinfection; drug resistance; HBV; hepatitis B; HIV; pediatrics; vaccine

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; GAMMA INTERFERON; HEPATITIS B VACCINE; LAMIVUDINE; PEGINTERFERON ALPHA2A; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ACTIVE IMMUNIZATION; ANTIVIRAL THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEPATITIS; HEPATITIS B; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LACTIC ACIDOSIS; MIXED INFECTION; MYALGIA; PREGNANT WOMAN; REVIEW; RIGOR; RISK FACTOR; STEATOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COINFECTION; FEMALE; HEPATITIS B; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; YOUNG ADULT;

EID: 84874633801     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.13.2     Document Type: Review

References (131)

1. WHO. Hepatitis B. WHO Fact Sheet 204 (2008). WHO, Geneva, Switzerland.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11(2), 97-107 (2004).
3. Burnett RJ, François G, Kew MC et al. Hepatitis B virus and human immunodef-ciency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int. 25(2), 201-213 (2005).
4. Martín-Carbonero L, Poveda E. Hepatitis B virus and HIV infection. Semin. Liver Dis. 32 (2), 114-119 (2012).
5. Thio CL. Hepatitis B in the human immunodefciency virus-infected patient: epidemiology, natural history, and treatment. Semin. Liver Dis. 23(2), 125-136 (2003).
6. Hadler SC, Judson FN, O'Malley PM et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodefciency virus infection. J. Infect. Dis. 163 (3), 454-459 (1991).
7. Attia KA, Eholié S, Messou E et al. Prevalence and virological profles of hepatitis B infection in human immunode-fciency virus patients. World J. Hepatol. 4(7), 218-223 (2012).
8. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodefciency virus-infected subjects. J. Infect. Dis. 188(4), 571-577 (2003).
9. Mayaphi SH, Roussow TM, Masemola DP, Olorunju SA, Mphahlele MJ, Martin DJ. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. S. Afr. Med. J. 102(3 Pt 1), 157-162 (2012).
10. Eke AC, Eke UA, Okafor CI, Ezebialu IU, Ogbuagu C. Prevalence, correlates and pattern of hepatitis B surface antigen in a low resource setting. Virol. J. 8, 12 (2011).
11. Sangaré L, Sombié R, Combasséré AW et al. Antenatal transmission of hepatitis B virus in an area of HIV moderate prevalence, Burkina Faso. Bull. Soc. Pathol. Exot. 102(4), 226-229 (2009).
12. Cho Y, Bonsu G, Akoto-Ampaw A et al. The prevalence and risk factors for hepatitis B surface Ag positivity in pregnant women in eastern region of Ghana. Gut Liver 6(2), 235-240 (2012).
13. MacLean B, Hess RF, Bonvillain E et al. Seroprevalence of hepatitis B surface antigen among pregnant women attending the Hospital for Women & Children in Koutiala, Mali. S. Afr. Med. J. 102(1), 47-49 (2012).
14. Mamadou S, Ide M, Maazou AR, Aoula B, Labo S, Bozari M. HIV infection and hepatitis B seroprevalence among antenatal clinic attendees in Niger, West Africa. HIV AIDS (Auckl.) 4, 1-4 (2012).
15. Adesina O, Oladokun A, Akinyemi O et al. Human immuno-defciency virus and hepatitis B virus coinfection in pregnancy at the University College Hospital, Ibadan. Afr. J. Med. Med. Sci. 39(4), 305-310 (2010).
16. Tiruneh M. Seroprevalence of multiple sexually transmitted infections among antenatal clinic attendees in Gondar Health Center, northwest Ethiopia. Ethiop. Med. J. 46(4), 359-366 (2008).
17. Ilboudo D, Karou D, Nadembega WM et al. Prevalence of human herpes virus-8 and hepatitis B virus among HIV seropositive pregnant women enrolled in the Mother-to-Child HIV Transmission Prevention Program at Saint Camille Medical Centre in Burkina Faso. Pak. J. Biol. Sci. 10(17), 2831-2837 (2007).
18. Simpore J, Savadogo A, Ilboudo D et al. Toxoplasma gondii, HCV, and HBV seroprevalence and co-infection among HIV-positive and-negative pregnant women in Burkina Faso. J. Med. Virol 78(6), 730-733 (2006).
19. Collenberg E, Ouedraogo T, Ganamé J et al. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: a comparative analysis. J. Med. Virol. 78(5), 683-692 (2006).
20. Simpore J, Granato M, Santarelli R et al. Prevalence of infection by HHV-8, HIV, HCV and HBV among pregnant women in Burkina Faso. J. Clin. Virol. 31(1), 78-80 (2004).
21. Pirillo MF, Bassani L, Germinario EA et al. Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J. Med. Virol 79(12), 1797-1801 (2007).
22. Kfutwah AK, Tejiokem MC, Njouom R. A low proportion of HBeAg among HBsAg-positive pregnant women with known HIV status could suggest low perinatal transmission of HBV in Cameroon. Virol. J. 9, 62 (2012).
23. Aurpibul L, Lumbiganon P, Kolasaraksa P et al. HIV and hepatitis B coinfection among perinatally HIV-infected Thai adolescents. Pediatr. Infect. Dis. J. 31(9), 943-947 (2012).
24. Zhou S, Zhao Y, He Y et al. Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodefciency virus-1 infection in China, 2005-2009. J. Acquir. Immune Defc. Syndr. 54(2), 191-196 (2010).
25. Bhargava A, Singh DK, Rai R. Sero-preva-lence of viral co-infections in HIV infected children of northern India. Indian J. Pediatr. 76(9), 917-919 (2009).
26. Mutwa PR, Boer KR, Rusine JB et al. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda. Pediatr. Infect. Dis. J. doi:10.1097/INF.0b013e 318271b93d (2012) (Epub ahead of print).
27. Ashir GM, Rabasa AI, Gofama MM, Bukbuk D, Abubakar H, Farouk GA. Study of hepatic functions and prevalence of hepatitis B surface antigenaemia in Nigerian children with human immunodefciency virus infection. Niger. J. Med. 18(3), 260-262 (2009).
28. Telatela SP, Matee MI, Munubhi EK. Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodefciency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Sal aam, Tanzania. BMC Public Health 7, 338 (2007).
29. Rouet F, Chaix ML, Inwoley A et al.; Programme Enfant Yopougon (Agence Nationale de Recherches sur le SIDA et les Hépatites Virales B et C 1244/1278). Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. Clin. Infect. Dis. 46(3), 361-366 (2008).
30. + T-cell counts and plasma HIV-1 RNA levels with serological HBeAg/anti-HBe patterns obtained in West-African HBV-HIV-1-co-infected children. J. Trop. Pediatr. 55(6), 409-412 (2009).
31. Chakraborty R, Rees G, Bourboulia D et al. Viral coinfections among African children infected with human immunodef-ciency virus type 1. Clin. Infect. Dis. 36(7), 922-924 (2003).
32. Nacro B, Dao B, Dahourou H. HBs antigen in children with suspicion of HIV infection. J. Trop. Pediatr. 47(5), 303-304 (2001).
33. Ruta SM, Matusa RF, Sultana C et al. High prevalence of hepatitis B virus markers in Romanian adolescents with human immunodefciency virus infection. MedGenMed 7(1), 68 (2005).
34. Toussi SS, Abadi J, Rosenberg M, Levanon D. Prevalence of hepatitis B and C virus infections in children infected with HIV. Clin. Infect. Dis. 45(6), 795-798 (2007).
35. WHO, Protocol 7 Management of hepatitis B and HIV coinfection. HIV/AIDS treatment and care. Clinical protocols for the WHO European Region (2012). WHO, Geneva, Switzerland.
36. Puoti M, Manno D, Nasta P, Carosi G. Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. Clin. Infect. Dis. 46(3), 367-369 (2008).
37. Kew MC. Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Gut 38(Suppl. 2), S31-S36 (1996).
38. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut 38(Suppl. 2), S5-S12 (1996).
39. Ayoola E. Viral hepatitis in Africa. In: Viral Hepatitis and Liver Disease. Aj Zuckerman E (Ed.). Alan R Liss, New York, NY, USA, 161-169 (1988).
40. Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, Sim J. Preimmunization epidemiology of hepatitis B virus infection in South African children. J. Med. Virol. 58(2), 111-115 (1999).
41. Beasley RP, Trepo C, Stevens CE, Szmuness W The e antigen and vertical transmission of hepatitis B surface antigen. Am. J. Epidemiol. 105(2), 94-98 (1977).
42. Wong VC, Ip HM, Reesink HW et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1(8383), 921-926 (1984).
43. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N. Engl. J. Med. 294(14), 746-749 (1976).
44. Xu DZ, Yan YP, Choi BC et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J. Med. Virol. 67(1), 20-26 (2002).
45. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J. Infect. Dis. 170(6), 1418-1423 (1994).
46. Wiseman E, Fraser MA, Holden S et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med. J. Aust. 190(9), 489-492 (2009).
47. Soriano V, Mocroft A, Peters L et al. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J. Antimicrob. Chemother. 65(3), 548-555 (2010).
48. Araujo NM, Waizbort R, Kay A. Hepatitis B virus infection from an evolutionary point of view: how viral, host, and environmental factors shape genotypes and subgenotypes. Infect. Genet. Evol. 11(6), 1199-1207 (2011).
49. WHO/UNICEF Coverage Estimates 2010 Revision (2011). WHO, Geneva, Switzerland.
50. Voigt AR, Strazer Neto M, Spada C, Treitinger A. Seroprevalence of hepatitis B and hepatitis C markers among children and adolescents in the south Brazilian region: metropolitan area of Florianopolis, Santa Catarina. Braz. J infect. dis. 14(1), 60-65 (2010).
51. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int. J. Infect. Dis. 16(2), e82-e88 (2012).
52. WHO/UNICEF Coverage Estimates 1980-2010 (2011). WHO, Geneva, Switzerland.
53. Ndirangu J, Bärnighausen T, Tanser F, Tint K, Newell ML. Levels of childhood vaccination coverage and the impact of maternal HIV status on child vaccination status in rural KwaZulu-Natal, South Africa&z.ast;. Trop. Med. Int. Health 14(11), 1383-1393 (2009).
54. Simani OE, Leroux-Roels G, François G, Burnett RJ, Meheus A, Mphahlele MJ. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine 27(1), 146-151 (2009).
55. Pippi F, Bracciale L, Stolzuoli L et al. Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania. HIV Med. 9(7), 519-525 (2008).
56. Abzug MJ, Warshaw M, Rosenblatt HM et al.; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J. Infect. Dis. 200(6), 935-946 (2009).
57. Fernandes SJ, Slhessarenko N, Souto FJ. Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine. Vaccine 26(8), 1032-1037 (2008).
58. Pessoa SD, Miyamoto M, Ono E, Gouvêa AF, de Moraes-Pinto MI, Succi RC. Persistence of vaccine immunity against hepatitis B virus and response to revaccina-tion in vertically HIV-infected adolescents on HAART Vaccine 28(6), 1606-1612 (2010).
59. Siriaksorn S, Puthanakit T, Sirisanthana T, Sirisanthana V Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 24(16), 3095-3099 (2006).
60. Lao-araya M, Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 25(29), 5324-5329 (2007).
61. Lao-Araya M, Puthanakit T, Aurpibul L, Taecharoenkul S, Sirisanthana T, Sirisanthana V Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy. Vaccine 29(23), 3977-3981 (2011).
62. McMahon BJ, Alward WL, Hall DB et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J. Infect. Dis. 151(4), 599-603 (1985).
63. Chang MH. Natural history of hepatitis B virus infection in children. J. Gastroenterol Hepatol. 15, e16-e19 (2000).
64. Ni YH. Natural history of hepatitis B virus infection: pediatric perspective. J. Gastroenterol. 46(1), 1-8 (2011).
65. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin. Infect. Dis. 20(4), 992-1000 (1995).
66. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 92(6), 1844-1850 (1987).
67. McMahon BJ. Natural history of chronic hepatitis B. Clin. Liver Dis. 14(3), 381-396 (2010).
68. Jaroszewicz J, Calle Serrano B, Wursthorn K et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J. Hepatol. 52(4), 514-522 (2010).
69. Tong MJ, Hsu L, Hsien C et al. A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatol. Int. 4(2), 516-522 (2010).
70. Antaki N, Zeidane N, Alhaj N et al. HBsAg titers in the different phases of hepatitis B infection in Syrian patients. J. Clin. Virol. 53(1), 60-64 (2012).
71. Jonas MM, Block JM, Haber BA et al.; Hepatitis B Foundation. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepa tology 52(6), 2192-2205 (2010).
72. Chang MH. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol. Int. 2(Suppl. 1), 28-36 (2008).
73. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48(2), 335-352 (2008).
74. Chu CM, Liaw YF. Natural history of chronic hepatitis B virus infection: an immunopathological study. J. Gastroenterol Hepatol. 12(9-10), S218-S222 (1997).
75. Bortolotti F, Guido M, Bartolacci S et al. Chronic hepatitis B in children after e antigen seroclearance: fnal report of a 29-year longitudinal study. Hepatology 43(3), 556-562 (2006).
76. Liang TJ. Hepatitis B: the virus and disease. Hepatology 49 (Suppl. 5), S13-S21 (2009).
77. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J. Hepatol. 44(Suppl. 1), S65-S70 (2006).
78. Thio CL. Hepatitis B and human immunodefciency virus coinfection. Hepatology 49(Suppl. 5), S138-S145 (2009).
79. Gatanaga H, Yasuoka A, Kikuchi Y, Tachikawa N, Oka S. Infuence of prior HIV-1 infection on the development of chronic hepatitis B infection. Eur. J. Clin. Microbiol. Infect. Dis. 19(3), 237-239 (2000).
80. Colin JF, Cazals-Hatem D, Loriot MA et al. Infuence of human immunodef-ciency virus infection on chronic hepatitis B in homosexual men. Hepatology 29(4), 1306-1310 (1999).
81. Thio CL, Seaberg EC, Skolasky R Jr et al.; Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360 (9349), 1921-1926 (2002).
82. Thio CL. Treatment of chronic hepatitis B in the HIV-infected patient. Hopkins HIV Rep. 15(4), 9, 12 (2003).
83. Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin. Infect. Dis. 39(1), 129-132 (2004).
84. Matthews GV, Avihingsanon A, Lewin SR et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 48(4), 1062-1069 (2008).
85. Dore GJ, Soriano V, Rockstroh J et al.; SMART INSIGHT study group. Frequent hepatitis B virus rebound among HIVhepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 24(6), 857-865 (2010).
86. Bellini C, Keiser O, Chave JP et al.; Swiss HIV Cohort Study. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med. 10(1), 12-18 (2009).
87. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 29(Suppl. 1), 100-107 (2009).
88. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 61(Suppl. 1), i6-i17 (2012).
89. Iorio R, Giannattasio A, Cirillo F, D' Alessandro L, Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin. Infect. Dis. 45(8), 943-949 (2007).
90. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142(6), 1293-1302.e4 (2012).
91. Fitzpatrick E, Quaglia A, Vimalesvaran S, Basso MS, Dhawan A. Transient elastogra-phy is a useful non-invasive tool for the evaluation of fbrosis in paediatric chronic liver disease. J. Pediatr. Gastroenterol. Nutr. 56(1), 72-76 (2012).
92. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep. 58(RR-4), 1-207 (2009).
93. Wiersma ST, McMahon B, Pawlotsky JM et al.; World Health Organization Department of Immunization, Vaccines and Biologicals. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int. 31(6), 755-761 (2011).
94. Mofenson LM, Brady MT, Danner SP et al.; Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society; American Academy of Pediatrics. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR. Recomm. Rep. 58(RR-11), 1-166 (2009).
95. Wang C, Fan R, Sun J, Hou J. Prevention and management of drug resistant hepatitis B virus infections. J. Gastroenterol. Hepatol. 27(9), 1432-1440 (2012).
96. Ko SY, Oh HB, Park CW, Lee HC, Lee JE. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrose-quencing. Clin. Microbiol. Infect. 18 (10), E404-E411 (2012).
97. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44(3), 703-712 (2006).
98. Sasadeusz J, Audsley J, Mijch A et al. The anti-HIV activity of entecavir: a multicen-tre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 22(8), 947-955 (2008).
99. Torre D, Tambini R. Interferon-α therapy for chronic hepatitis B in children: a meta-analysis. Clin. Infect. Dis. 23(1), 131-137 (1996).
100. Sokal EM, Conjeevaram HS, Roberts EA et al. Interferon α therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 114(5), 988-995 (1998).
101. Di Martino V, Thevenot T, Colin JF et al. Infuence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 123 (6), 1812-1822 (2002).
102. Lau GK. Treatment of immunosuppressed chronic hepatitis B patients. Med. J. Malaysia 60(Suppl. B), 57-62 (2005).
103. Jonas MM, Kelly D, Pollack H et al. Effcacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. Pediatr. Infect. Dis. J. 31(6), 578-582 (2012).
104. Sokal EM, Kelly DA, Mizerski J et al. Long-term lamivudine therapy for children with HBeAg positive chronic hepatitis B. Hepatology 43(2), 225-232 (2006).
105. Matthews GV, Bartholomeusz A, Locarnini S et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20(6), 863-870 (2006).
106. Sheng YJ, Liu JY, Tong SW et al. Lamivu-dine plus adefovir combination therapy versus entecavir monotherapy for lamivu-dine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol. J. 8, 393 (2011).
107. Sheldon J, Camino N, Rodés B et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir. Ther. (Lond.) 10(6), 727-734 (2005).
108. Jonas MM, Kelley DA, Mizerski J et al.; International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N. Engl. J. Med. 346(22), 1706-1713 (2002).
109. Matthews GV, Manzini P, Hu Z et al.; PHIDISA II study team. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 25(14), 1727-1735 (2011).
110. Jonas MM, Kelly D, Pollack H et al. Safety, effcacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 47(6), 1863-1871 (2008).
111. Kahn J, Lagakos S, Wulfsohn M et al. Effcacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 282(24), 2305-2312 (1999).
112. Pawlowska M, Halota W, Smukalska E, Wozniakowska-Gesicka T, Kups J. HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. Eur. J. Clin. Microbiol. Infect. Dis. 31(4), 571-574 (2012).
113. Lange CM, Bojunga J, Hofmann WP et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 50(6), 2001-2006 (2009).
114. Pessôa MG, Gazzard B, Huang AK et al. Effcacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 22(14), 1779-1787 (2008).
115. Ratcliffe L, Beadsworth MB, Pennell A, Phillips M, Vilar FJ. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 25(8), 1051-1056 (2011).
116. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359(23), 2442-2455 (2008).
117. Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig. Dis. Sci. 55(10), 2727-2734 (2010).
118. Brook G, Main J, Nelson M et al.; BHIVA Viral Hepatitis Working Group. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med. 11(1), 1-30 (2010).
119. Murray KF, Szenborn L, Wysocki J et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 56(6), 2018-2026 (2012).
120. HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children-A Working Group of the Offce of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection (2012).
121. World Health Organisation. Antiretroviral therapy for HIV infection in infants and children: towards universal access: recommendations for a public health approach (2010 revision). WHO, Geneva, Switzerland.
122. Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodefciency virus-infected patients. Hepatology 30(5), 1302-1306 (1999).
123. Iacomi F, Vincenti D, Vairo F et al. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resist-ant chronic hepatitis B. J. Med. Virol. 81(7), 1151-1156 (2009).
124. Schmutz G, Nelson M, Lutz T et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 20(15), 1951-1954 (2006).
125. Quiros-Roldan E, Calabresi A, Lapadula G et al. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by H I V. Antivir. Ther. (Lond.) 13(3), 341-348 (2008).
126. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J. Med. Virol. 79(11), 1650-1654 (2007).
127. Torresi J, Earnest-Silveira L, Civitico G et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the 'fngers' subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299(1), 88-99 (2002).
128. Sayan M, Akhan SC. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B. Int. J. Infect. Dis. 15(10), e722-e726 (2011).
129. Torresi J. Hepatitis B antiviral resistance and vaccine escape: two sides of the same coin. Antivir. Ther. (Lond.) 13(3), 337-340 (2008).
130. Frange P, Chaix ML, Blanche S. Preserving future therapeutic options: should we limit the 3TC use in young HIV-1 infected children initiating frst-line HAART? AIDS 27(2), 151-154 (2012).
131. Rockstroh JK, Bhagani S, Benhamou Y et al.; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 9(2), 82-88 (2008).